Drug Discovery
Drug Discovery covers where GLP-1 came from and where it’s going. Single-agonist (semaglutide), dual-agonist (tirzepatide), triple-agonist (retatrutide in trials), and oral small-molecule (orforglipron, just approved as Foundayo) — each represents a different bet on maximizing efficacy while managing side effects. We explain mechanisms and track the late-stage pipeline.
Do GLP-1 Drugs Cause Cancer? Honest Answer.
A boxed warning, scary headlines, anxious social-media posts. The real cancer evidence on GLP-1 drugs is more nuanced — and…
Latest in Drug Discovery
GLP-1 in 2026: 5 Big Changes Coming Soon
A new pill, a far more powerful drug in trials, a Medicare pilot, a tightening line on compounding. The GLP-1…
Compounded Semaglutide from $147/month
More from Drug Discovery
Traveling with GLP-1? How to Keep It Safe
Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you…
Where to Inject GLP-1: The Site Rotation Guide
Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you…
Missed Your GLP-1 Shot? Here’s What to Do
Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you…
First Semaglutide Shot? Here’s the Pen Guide
Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you…
GLP-1 Long-Term Safety: What We Don’t Know Yet
Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you…